IC 86621

IC 86621 is a potent DNA-dependent protein kinase (DNA-PK) inhibitor, with an IC50 of 120 nM. IC 86621 also acts as a selective and reversible ATP-competitive inhibitor.IC 86621 inhibits DNA-PK mediated cellular DNA double-strand break (DSB) repair (EC50=68 μM) . IC 86621 increases DSB-induced antitumor activity without cytotoxic effects. IC 86621 can protects rheumatoid arthritis (RA) T cells from apoptosis[1][2].

Product Specifications

CAS Number

[404009-40-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Apoptosis; DNA-PK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ic-86621.html

Purity

99.06

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C1=CC=C(N2CCOCC2)C=C1O)=O

Molecular Formula

C12H15NO3

Molecular Weight

221.26

Precautions

H302, H315, H319

References & Citations

[1]Chandra G, et al. Improved synthesis of a DNA-dependent protein kinase inhibitor IC86621. Arch Pharm Res. 2012 Mar;35 (4) :639-45.|[2]Shao L, et al. DNA-dependent protein kinase catalytic subunit mediates T-cell loss in rheumatoid arthritis. EMBO Mol Med. 2010 Oct;2 (10) :415-27.